Literature DB >> 26101575

Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug Candidates.

Keisuke Hamada1, Akihiro Taguchi1, Masaya Kotake1, Suguru Aita1, Saori Murakami1, Kentaro Takayama1, Fumika Yakushiji1, Yoshio Hayashi1.   

Abstract

(+)-Negamycin (1), a natural dipeptidic antibiotic bearing a hydrazide structure, exhibits a readthrough activity toward the nonsense mutation of the dystrophin gene and restores dystrophin expression in muscles of Duchenne muscular dystrophy model mdx mice. Herein to develop more potent readthrough compounds, we performed a structure-activity relationship (SAR) study of 3-epi-deoxynegamycin (2), which is also another natural readthrough compound with little antimicrobial activity, focusing on the main carbon chain length. We found that one carbon atom shorter derivative 9b shows a higher readthrough activity than 1 and 2. Further derivatization at the carboxylic acid part of 9b demonstrates that its meta-chlorobenzyl ester derivative 17e, which has a higher ClogP value, exhibits a more potent readthrough activity than 9b. Interestingly, in the cell-free protein expression system, the readthrough activity of 17e drastically decreases compared to that in the cell-based assay. These results suggest that benzyl ester-type derivatives enhance the hydrophobicity and function as prodrugs to produce active compound 9b in living cell systems.

Entities:  

Keywords:  (+)-Negamycin; 3-epi-deoxynegamycin; Duchenne muscular dystrophy; prodrug; readthrough drug

Year:  2015        PMID: 26101575      PMCID: PMC4468409          DOI: 10.1021/acsmedchemlett.5b00121

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  22 in total

Review 1.  Nonsense-mediated mRNA decay in health and disease.

Authors:  P A Frischmeyer; H C Dietz
Journal:  Hum Mol Genet       Date:  1999       Impact factor: 6.150

2.  Germinal mosaicism increases the recurrence risk for 'new' Duchenne muscular dystrophy mutations.

Authors:  E Bakker; H Veenema; J T Den Dunnen; C van Broeckhoven; P M Grootscholten; E J Bonten; G J van Ommen; P L Pearson
Journal:  J Med Genet       Date:  1989-09       Impact factor: 6.318

3.  Efficient total synthesis of (+)-negamycin, a potential chemotherapeutic agent for genetic diseases.

Authors:  Yoshio Hayashi; Thomas Regnier; Shigenobu Nishiguchi; Magne O Sydnes; Daisuke Hashimoto; Junya Hasegawa; Takahiro Katoh; Tetsuya Kajimoto; Masataka Shiozuka; Ryoichi Matsuda; Manabu Node; Yoshiaki Kiso
Journal:  Chem Commun (Camb)       Date:  2008-03-18       Impact factor: 6.222

4.  [A new method for synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazoles as additives].

Authors:  W König; R Geiger
Journal:  Chem Ber       Date:  1970

5.  A new antibiotic, negamycin.

Authors:  M Hamada; T Takeuchi; S Kondo; Y Ikeda; H Naganawa
Journal:  J Antibiot (Tokyo)       Date:  1970-03       Impact factor: 2.649

6.  Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

Authors:  M Manuvakhova; K Keeling; D M Bedwell
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

7.  Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.

Authors:  Igor Nudelman; Dana Glikin; Boris Smolkin; Mariana Hainrichson; Valery Belakhov; Timor Baasov
Journal:  Bioorg Med Chem       Date:  2010-03-27       Impact factor: 3.641

8.  Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice.

Authors:  Masayuki Arakawa; Masataka Shiozuka; Yuki Nakayama; Takahiko Hara; Masa Hamada; Shin'ichi Kondo; Daishiro Ikeda; Yoshikazu Takahashi; Ryuichi Sawa; Yoshiaki Nonomura; Kianoush Sheykholeslami; Kenji Kondo; Kimitaka Kaga; Toshio Kitamura; Yuko Suzuki-Miyagoe; Shin'ichi Takeda; Ryoichi Matsuda
Journal:  J Biochem       Date:  2003-11       Impact factor: 3.387

Review 9.  Aminoglycosides: nephrotoxicity.

Authors:  M P Mingeot-Leclercq; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

10.  Readthrough of premature termination codons in the adenomatous polyposis coli gene restores its biological activity in human cancer cells.

Authors:  Célia Floquet; Jean-Pierre Rousset; Laure Bidou
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

View more
  4 in total

Review 1.  Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.

Authors:  Akihiro Taguchi; Keisuke Hamada; Yoshio Hayashi
Journal:  J Antibiot (Tokyo)       Date:  2017-09-27       Impact factor: 2.649

2.  Structure-Activity Relationship Study of Leucyl-3-epi-deoxynegamycin for Potent Premature Termination Codon Readthrough.

Authors:  Akihiro Taguchi; Keisuke Hamada; Masataka Shiozuka; Misaki Kobayashi; Saori Murakami; Kentaro Takayama; Atsuhiko Taniguchi; Takeo Usui; Ryoichi Matsuda; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2017-09-29       Impact factor: 4.345

3.  New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.

Authors:  Keisuke Hamada; Noriko Omura; Akihiro Taguchi; Alireza Baradaran-Heravi; Masaya Kotake; Misaki Arai; Kentaro Takayama; Atsuhiko Taniguchi; Michel Roberge; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2019-09-23       Impact factor: 4.345

Review 4.  Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy.

Authors:  John Hyun Namgoong; Carmen Bertoni
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.